Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
Information Letter on acitretin and teratogenicity: Extension of the contraception period and the prohibition of blood donation after end of therapy
2016.11.08
Active substance: acitretin
In an Information Letter, the companies Dermapharm and Puren Pharma point out the extension of the contraception period and the prohibition of blood donation up to three years after discontinuation of therapy with acitretin.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN